Intervention Review

Antidepressants for people with both schizophrenia and depression

  1. Caroline Whitehead1,
  2. Susannah Moss2,
  3. Alastair Cardno3,
  4. Glyn Lewis4,
  5. Vivek A Furtado5,*

Editorial Group: Cochrane Schizophrenia Group

Published Online: 22 APR 2002

Assessed as up-to-date: 6 FEB 2002

DOI: 10.1002/14651858.CD002305


How to Cite

Whitehead C, Moss S, Cardno A, Lewis G, Furtado VA. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002305. DOI: 10.1002/14651858.CD002305.

Author Information

  1. 1

    University of Bristol, Division of Psychiatry, Bristol, UK

  2. 2

    Cardiff University, Occupational Health Psychology, Cardiff, UK

  3. 3

    Leeds Institute of Health Sciences, University of Leeds, Academic Unit of Psychiatry and Behavioural Sciences, Leeds, UK

  4. 4

    University of Bristol, School of Social and Community Medicine, Bristol, UK

  5. 5

    Rampton Hospital, Forensic Psychiatry, Retford, Nottinghamshire, UK

*Vivek A Furtado, Forensic Psychiatry, Rampton Hospital, Woodbeck, Retford, Nottinghamshire, DN22 0PD, UK. furtado.v@gmail.com. vivek.furtado@nhs.net.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 22 APR 2002

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stefan Leucht, Roland Vauth, Hans Michael Olbrich, Markus Jäger, Psychische Erkrankungen, 2015,

    CrossRef

  2. 2
    Gaurava Agarwal, Megan Pirigyi, Herbert Meltzer, Schizophrenia and Suicide: Treatment Optimization, Current Treatment Options in Psychiatry, 2014, 1, 2, 149

    CrossRef

  3. 3
    Seth Himelhoch, Eric Slade, Julie Kreyenbuhl, Deborah Medoff, Clayton Brown, Lisa Dixon, Antidepressant prescribing patterns among VA patients with schizophrenia, Schizophrenia Research, 2012, 136, 1-3, 32

    CrossRef

  4. 4
    Stefan Leucht, Jürgen Fritze, Mario Horst Lanczik, Roland Vauth, Hans Michael Olbrich, Psychische Erkrankungen, 2012,

    CrossRef

  5. 5
    Viacheslav Terevnikov, Jan-Henry Stenberg, Jari Tiihonen, Marina Joffe, Mark Burkin, Evgueni Tchoukhine, Grigori Joffe, Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase, Human Psychopharmacology: Clinical and Experimental, 2011, 26, 3
  6. 6
    G. S. Malhi, D. Adams, R. Porter, A. Wignall, L. Lampe, N. O’Connor, M. Paton, L. A. Newton, G. Walter, A. Taylor, M. Berk, R. T. Mulder, Clinical practice recommendations for depression, Acta Psychiatrica Scandinavica, 2009, 119,
  7. 7
    Diego Novick, Manuel Bousono, David Suarez, Jose M. Olivares, Angel L. Montejo, Josep Maria Haro, Eric T. Edgell, Mark Ratcliffe, Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 6, 972

    CrossRef

  8. 8
    Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel-Kluge, Hany George El-Sayeh, Stefan Leucht, Jun Xia, Aripiprazole versus other atypical antipsychotics for schizophrenia, The Cochrane Library,
  9. 9
    Priya Khanna, Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Sandra Schwarz, Hany George El-Sayeh, Stefan Leucht, Aripiprazole versus other atypical antipsychotics for schizophrenia, The Cochrane Library,
  10. 10
    Magdolna Tardy, Maximilian Huhn, Werner Kissling, Rolf R Engel, Stefan Leucht, Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia, The Cochrane Library,